CDK6 and glioblastoma: Accordingly, herein we describe the ability of the FDA approved drug topotecan to act as a novel inhibitor of global SUMOylation, as well as its putative role as an adjuvant therapy in GBM treatment regimens via the inhibition of global SUMOylation, CDK6, and HIF-1α.